Roivant Sciences Ltd. 8-K

What Happened

• On March 3, 2026, Roivant’s subsidiary Genevant Sciences GmbH and Arbutus Biopharma (together “Genevant/Arbutus”) and Moderna (Moderna, Inc. and ModernaTx, Inc.) entered a settlement to resolve worldwide patent infringement litigation over lipid nanoparticle (LNP) technology used in Moderna vaccines (the “LNP Litigation”).
• Under the Settlement Agreement Moderna will pay Genevant/Arbutus a $950.0 million noncontingent lump sum on or before July 8, 2026, plus a contingent lump sum of up to $1.3 billion (the “Contingent Payment”) tied to the Federal Circuit’s handling of Moderna’s 28 U.S.C. §1498 defense on certain doses. Moderna may appeal only on the §1498 issue described in the agreement. The Contingent Payment may be prorated or required to be returned with interest under certain reversal scenarios.
• The agreement includes mutual releases and a fully paid-up, royalty-free, irrevocable, non-exclusive, worldwide license and covenant not to sue from Genevant/Arbutus to Moderna covering SM-102‑based LNP formulations for specified mRNA vaccines (including Spikevax®, mNEXSPIKE and mRESVIA) that meet certain conditions.

Key Details

• $950.0 million noncontingent cash payment due on or before July 8, 2026.
• Up to $1.3 billion contingent payment tied to a Genevant/Arbutus “§1498 Victory” at the Federal Circuit (or failure to timely appeal); prorated or subject to repayment if appellate outcomes change.
• Royalty‑free, irrevocable worldwide license and covenant not to sue for SM-102‑based LNP vaccines (including Spikevax and specified Moderna products).
• Roivant’s board increased the common share repurchase program to up to $1.0 billion (inclusive of the prior $500M authorization); funded with cash on hand, no expiration date, purchases may use tender offers, open market trades, private transactions or Rule 10b5-1 plans.

Why It Matters

• The settlement converts significant litigation exposure into near‑term cash ($950M) and potential additional cash (up to $1.3B) subject to appellate outcomes and clawback risk — a material balance‑sheet and cash‑flow event for Roivant’s subsidiary interests.
• The royalty‑free license removes a major ongoing patent threat between the parties for SM‑102 LNP vaccines, meaning Moderna can continue commercializing specified products without future royalty payments to Genevant/Arbutus under those patents.
• The expanded $1.0B buyback program signals management intends to return capital to shareholders using available cash, but repurchases are discretionary, may be suspended, and the timing/amounts are not guaranteed.